The Haute Autorité de Santé gives the green light to three vaccines adapted to Omicron

The Haute Autorité de Santé is giving the green light to three anti-Covid vaccines adapted to Omicron for a new booster vaccination campaign planned for the fall and coupled with that against the flu, it announced this Tuesday, September 20 in a statement.

This new booster dose will be recommended to people at risk of a severe form, to those around them and to caregivers. The HAS recommends “indifferently one of the three bivalent vaccines” – two developed by Pfizer/BioNTech, the third by Moderna – recently validated by the European Medicines Agency.

“Based on the available data and in an epidemic context marked by the majority circulation of the BA.5 sub-variant”HAS recommends using “preferably” one of these vaccines, all messenger RNA, for a new fall booster dose. This recommendation applies regardless of the anti-Covid vaccine initially administered to the person.

Covid, monkey pox, Lyme… Are we doomed to suffer from zoonoses?

“Like seasonal influenza vaccines, updated each year to take into account the viruses that are most likely to circulate during the winter, bivalent mRNA vaccines are not new vaccines but vaccines adapted to the strains circulating »underlines the HAS in its press release.

Combine with flu vaccination

These are the vaccines from Moderna and Pfizer/BioNTech targeting the original strain of the virus and the BA.1 variant of Omicron, and the vaccine from Pfizer/BioNTech targeting the original strain and the BA subvariants .4 and BA.5 from Omicron.

The HAS is also maintaining its recommendation to combine the booster vaccination campaign against Covid-19 with that of vaccination against influenza, which will start on October 18. A concomitant injection or the same day of the two vaccines is possible, she recalls.

Covid: should we offer a fourth dose to everyone?

“Immediately and because the number of cases of infections has started to rise again for a few days”, this health authority recommends not postponing the second booster dose in the over 60s and under 60s at risk of a severe form who have not received it within the recommended time frame. It recalls the effectiveness of current vaccines (monovalent) against severe forms of Covid-19.

Leave a Comment